News & Views
Telix today announces its financial results for the half-year ended 30 June 2023. All figures are in AUD$ unless otherwise…
Read more
Telix today advises that it will release its financial results for the half-year ended 30 June 2023 on Wednesday 23 August…
Read more
Telix today announces that a first patient has been dosed in China in the pivotal Phase III registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11), for the…
Read more
Telix today announces that a first patient has been dosed in a Phase I study of the Company’s investigational therapy TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) in combination with post-surgical standard…
Read more
Telix today issues its Appendix 4C quarterly cash flow report and accompanying Activities Report for the quarter ended 30 June 2023 (Q2 2023). All figures are in AUD$ unless otherwise…
Read more
Telix today announces that the first patient has been dosed in a Phase I study of the Company’s investigational targeted radiation therapy, TLX250, in combination with a Merck KGaA, Darmstadt,…
Read more
Telix today advises it will release its Appendix 4C Quarterly Cash Flow Report and Activities Report for the period ended 30 June 2023 on Wednesday 19 July 2023 at market…
Read more
today announces further details of the positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier:…
Read more
Telix is pleased to provide a video recording of the Company’s briefing session for shareholders held on Wednesday, June 21, 2023, at The Yale Club in New York City….
Read more
Telix today announces presentations from the Company’s investigational prostate (prostate specific-membrane antigen, or PSMA-targeting) and renal (carbonic anhydrase IX, or CAIX-targeting) diagnostic and therapeutic programs at the Society of Nuclear…
Read more